Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

A. Palma, David; Olson, Robert; Harrow, Stephen; Correa, Rohann; L. Schneiders, Famke; J.A. Haasbeek, Cornelis; Rodrigues, George; Lock, Michael; Yaremko, Brian; Bauman, Glenn; Ahmad, Belal; Schellenberg, Devin; Liu, Mitchell; Gaede, Stewart; Laba, Joanna; Mulroy, Liam; Senthi, Sashendra; V. Louie, Alexander; Swaminath, Anand; J. Chalmers, Anthony; Warner, Andrew; J. Slotman, Ben; D. de Gruijl, Tanja; L. Allan, Alison; Senan, Suresh

doi:10.1186/s12885-019-5977-6

Public

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Published in BMC Cancer • Aug 19, 2019

Authors:

David A. Palma

Robert Olson

Stephen Harrow

Abstract

BACKGROUND: Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized ...

Subject

SABR volatility model

Medicine

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!